TOI
$3.59
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States.
Intraday
Recent News
Oncology Institute (TOI) Earnings Transcript
Daniel Virnich: Thank you, Mark. Good afternoon, everyone, and thank you for joining our fourth quarter and full year 2025 earnings call. Most importantly, the fourth quarter marked an important milestone being our first profitable quarter as a public company from an adjusted EBITDA perspective.
The Oncology Institute Inc (TOI) Q4 2025 Earnings Call Highlights: Record Revenue and First ...
The Oncology Institute Inc (TOI) reports a milestone quarter with significant revenue growth and strategic expansions, despite upcoming challenges.
Oncology Institute Q4 Earnings Call Highlights
The Oncology Institute (NASDAQ:TOI) reported fourth-quarter and full-year 2025 results highlighted by what management described as its first profitable quarter as a public company on an adjusted EBITDA basis, alongside continued growth in its capitated and pharmacy dispensing businesses. CEO Daniel
Alignment Healthcare (ALHC) Reports Q4 Loss, Beats Revenue Estimates
Alignment Healthcare (ALHC) delivered earnings and revenue surprises of +67.04% and +1.10%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Is Oncology Institute (TOI) Quietly Rewiring Its Edge Around AI Talent And Boardroom Financial Discipline?
The Oncology Institute, Inc. recently promoted long-time technology leader Rakesh Panda to Chief Information Officer and Nolan Mariano to Chief People Officer, while also adding RadNet CFO Mark Stolper to its Board of Directors. These leadership moves highlight a growing emphasis on AI-enabled technology, data privacy, and talent management, combined with additional healthcare finance expertise at the board level. We’ll now explore how the CIO’s AI-focused mandate and the new board...